In a bold move to bolster its presence in the growing equine healthcare market, U.K.-based pharmaceutical group Animalcare has agreed to acquire Australian veterinary company Randlab for 120 million Australian dollars (approximately £62 million). This acquisition will expand Animalcare’s portfolio of products and deepen its reach in the global market.

Acquisition Agreement and Financing Details

On Tuesday, Animalcare announced that its Australian subsidiary, Animalcare Australia Pty Ltd., had entered into a “conditional share purchase agreement” to acquire Randlab. The deal is set to be funded through a mix of Animalcare’s cash reserves, committed debt facilities, and proceeds from a share placing. This placing, also launched on Tuesday, will raise an estimated £20 million through an accelerated bookbuild process.

Leading the legal guidance for Animalcare in this significant transaction are Squire Patton Boggs LLP, with teams in both Sydney and the U.K. The Sydney team, including partners Michael Gajic, Ashley Rose, and director Louisa Hine, is overseeing the deal, while the U.K. corporate team, led by Hannah Kendrick and Ben Morgan, is advising on the share placing.

Closing Timeline and Conditions

The deal, slated for completion in early January, remains contingent on Randlab’s performance through the five-month period ending in November. Animalcare expects that the transaction will close without requiring shareholder or regulatory approval.

Jenny Winter, CEO of Animalcare, expressed strong enthusiasm for the acquisition, calling Randlab a “market-leading” asset poised for substantial earnings in an expanding sector. She added that the deal would significantly enhance Animalcare’s equine market presence and open new commercial opportunities in an aligned regulatory environment.

Randlab’s Role in the Equine Healthcare Market

Randlab specializes in the production of veterinary drugs for horses and other equine species, offering both prescription and over-the-counter products such as antibiotics, sedatives, and anesthetics. Randlab’s primary trading company, Randlab Pty Ltd., accounts for 85% of its total sales, with additional revenue generated from its New Zealand subsidiary and a modest presence in the UAE.

Angelo Vasili, CEO and Managing Director of Randlab, expressed confidence in Animalcare’s ability to continue fostering Randlab’s unique offerings in Australia, New Zealand, and the UAE, adding that the company’s acquisition by Animalcare was the right fit for both businesses.

Market Potential and Future Growth

The global equine healthcare market is on a promising growth trajectory, with Grand View Research estimating the market size at $3.4 billion in 2023. The sector is projected to grow at a compound annual growth rate of 8.32% between 2024 and 2030, driven by advancements in research and development, increasing equine health issues, and the rise of artificial intelligence in the field.

Animalcare’s Ongoing Expansion Strategy

The acquisition of Randlab aligns with Animalcare’s broader strategy of expanding its product offerings and presence in the rapidly growing equine healthcare market. Earlier this year, the company sold its majority stake in pet microchipping business Identicare Ltd. for £24.9 million ($31.5 million) to focus on its core veterinary business.

As Animalcare finalizes the Randlab acquisition, the company looks to strengthen its position in a market that promises considerable growth in the years ahead. The outcome of this deal could pave the way for further acquisitions and partnerships as Animalcare continues to build a stronger foothold in the global veterinary industry.

Randlab did not immediately respond to requests for comment regarding the acquisition.